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Abstract 
Vascular endothelial growth factor (VEGF) is one of the most important mediators of angi-
ogenesis. Single-chain (sc)-VEGF protein containing an N-terminal Cys-tag has been designed 
for site-specific modification with a variety of imaging and therapeutic moieties. Site-specific 
labeling of scVEGF with thiol-reactive prosthetic group, N-[2-(4-
18F-fluorobenzamido) ethyl] 
maleimide  ([
18F]FBEM)  for positron  emission  tomography  (PET)  imaging of  VEFGR  may 
provide a new tracer which has great potential for clinical translation.  
Methods: [
18F]FBEM-scVEGF was synthesized by site-specific conjugation of 
18F-FBEM to a 
thiol group in Cys-tag of scVEGF at room temperature. The functional activity after labeling 
was tested by immunofluorescence staining, cellular uptake and efflux. The tumor targeting 
and  in  vivo  properties  were  evaluated  by  biodistribution  and  microPET  studies  in  tu-
mor-bearing mice.  
Results: The radiolabeling yield and specific activity of [
18F]FBEM-scVEGF were 20.6 ± 15.1% 
(based on starting [
18F]FBEM, uncorrected, n = 5) and 58.8 ± 12.4 GBq/µmol, respectively. 
Noninvasive  microPET  and  direct  tissue  sampling  experiments  demonstrated  that 
[
18F]FBEM-scVEGF had VEGFR specific tumor uptake in MDA-MB-435, U87MG and 4T1 
xenograft models. The optimal tumor uptake was achieved at 2 h p.i., which can be partially, 
but  significantly  blocked  by  co-injection  of  non-labeled  scVEGF  protein.  Overall, 
[
18F]FBEM-scVEGF showed VEGFR specific tumor uptake.  
Conclusion: The scVEGF was site-specifically labeled with 
18F via [
18F]FBEM prosthetic group 
and the tracer [
18F]FBEM-scVEGF exhibited high receptor binding affinity and tumor targeting 
efficacy. Further study of [
18F] FBEM-scVEGF to evaluate angiogenesis in cancer and other 
disease types is warranted. 
Key words: Site-specific protein labeling, FBEM-scVEGF, PET imaging, VEGFR. 
INTRODUCTION 
Vascular endothelial growth factors (VEGFs) are 
the most common cancer causing angiogenic factors, 
and  their  receptors  (VEGFRs)  are  overexpressed  in 
tumor-associated endothelial cells [1-3]. VEGFRs are 
tyrosine kinases that mediate most of the proangio-
genic activity of VEGF. The critical role of VEGFRs in 
tumor angiogenesis and their overexpression on the 
surface of angiogenic endothelial cells have rendered 
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VEGFRs  primary  targets  for  anti-angiogenic  thera-
pies. A non-invasive method for assessing the pres-
ence,  location(s),  extent,  and  intensity  of  increased 
VEGF receptor expression would be of clinical value, 
particularly in cancer. Serial imaging of VEGF recep-
tors expression could also be quite helpful in guiding 
cancer management.  
Over the last several years, significant advances 
have been achieved in developing novel probes for 
multimodality molecular imaging of VEGFR expres-
sion.  VEGF121  based  probes  have  been  prepared  to 
monitor the treatment efficacy and to identify patients 
who  may  benefit  from  the  VEGF/VEGFRs  targeted 
therapy; for example,  64Cu labeled VEGFR-2 specific 
VEGF121 mutant and VEGF121/Gelonin fusion protein 
labeled  with  64Cu  and  MnFe2O4  nanoparticles 
(VEGF121/rGel-MNPs)  have  been  used  for  VEGFRs 
PET  and  PET/MRI  dual  modality  imaging,  respec-
tively  [4,  5].  Radiolabeled  anti-VEGF/VEGFR  anti-
bodies, such as 89Zr-labeled bevacizimab showed the 
ability to determine VEGF expression levels in xeno-
graft  tumors  and  to  predict  tumor  response  to 
VEGF-targeted  anti-angiogenic  therapy  [6,  7].  Small 
molecule  VEGFR  antagonist  such  as  11C-labeled 
Vandetanib has been synthesized, although no in vivo 
PET imaging data was presented [8].  
Backer et al. [9] engineered a single chain VEGF 
(scVEGF), composed of 2 fused 3- to 112- amino acid 
fragments  of  VEGF121  and  an  N-terminal  15-amino 
acid Cys tag containing a unique cysteine residue for 
the site-specific attachment of a variety of agents, e.g., 
64Cu, 99mTc, 68Ga etc. for PET imaging, Cy5.5 for opti-
cal  imaging  [10],  and  microbubbles  for  ultrasound 
imaging [11]. scVGEF-based tracers bind to and are 
internalized  by  VEGFRs,  providing  information  on 
the prevalence and distribution of active regions  of 
ongoing angiogenesis in vivo.  
In this study, our aim is to determine whether 
18F-radiolabeled scVEGF-based tracers could be used 
to image VGEFRs in tumor models. This study is the 
first attempt to synthesize a novel [18F]FBEM-scVEGF, 
as well as its in vitro and in vivo characterization. The 
use of 18F offers a number of advantages as a PET ra-
dionuclide,  primarily  because  of  its  low  β+  energy 
(0.64 Mev), almost 100% positron efficiency; and its 
physical half-life (t1/2 = 109.7 min) is ideally suited for 
peptide and some protein labeling and PET imaging 
[12].  In  addition,  18F  is  routinely  applied  in  clinical 
oncology in the form of fluorodeoxyglucose (FDG), a 
Food  and  Drug  Administration  (FDA)-approved 
glucose analog. Therefore, it is widely used and read-
ily  available.  Despite  of  many  advantages  of 
18F-labeled  molecular  imaging  probes,  most  VEGFR 
imaging radiotracers reported to date are labeled with 
radiometals, such as 99mTc, 64Cu, or 68Ga. Because the 
physical  properties  and  labeling  strategies  of 
non-metallic radioisotopes, such as 18F, are quite dif-
ferent from those of radiometals, it is worthwhile to 
explore  the  feasibility  and  quality  of  18F  labeled 
VEGFR imaging probes. 
MATERIALS AND METHODS  
General 
Unless otherwise specified, all reagents were of 
analytical grade and were obtained from commercial 
sources.  Lyophilized  [C4]-Monothiol  Cys-tagged 
scVEGF and Cy5.5-scVEGF were provided by SibTech 
Inc. [18F]F- radionuclide was obtained from the NIH 
clinical center cyclotron facility by proton irradiation 
of 18O-enriched water. Reversed-phase extraction C18 
Sep-Pak  cartridges  were  obtained  from  Waters  Inc. 
and pretreated with ethanol and water before use. The 
syringe filter and polyethersulfone membranes (pore 
size, 0.22 mm; diameter, 13 mm) were obtained from 
Nalge Nunc International. Analytical reversed-phase 
high-performance liquid chromatography (RP-HPLC) 
was  performed  on  a  Waters  600  chromatography 
system  with  Waters  996  photodiode  array  detector 
and Beckman170 radioisotope detector.  
Preparation of FBEM-scVEGF 
Lyophilized [C4]-Monothiol Cys-tagged scVEGF 
(MW  28  kDa,  SibTech  Inc)  was  reconstituted  in 
phosphate  buffered  saline  (PBS)  to  a  final  protein 
concentration of 1 mg/mL. scVEGF (100 µg, 3.6 nmol) 
was  treated  with  FBEM 
(N-[2-(4-fluorobenzamide)ethyl]maleimide) (3 eq.) in 
100  µL  degassed  PBS.  The  reaction  stood  at  room 
temperature  for  1.25  h.  The  reaction  mixture  was 
loaded onto a NAP-5 (GE) column and after the reac-
tion volume had loaded onto the column and addi-
tional 150 µL saline was added. The subsequent ali-
quots of 250 uL saline were added to elute the prod-
uct. The fourth fraction contained the highest UV ab-
sorbance and was analyzed as the product.  
Preparation of 18F-FBEM-scVEGF  
[18F]FBEM was prepared as previously described 
[13]. [18F]FBEM (577 - 1435 MBq) in methylene chlo-
ride was transferred to a 1 mL Eppendorf tube and 
evaporated with argon flow at room temperature. The 
residual radioactivity was dissolved in 10 µl of etha-
nol; a solution of scVEGF (100 - 200 µg in 100 µL) PBS 
was added; and the mixture was allowed to react at 
room temperature for 30 min. At the end of that time, 
the reaction mixture was loaded onto a NAP-5 col-
umn (GE) prewashed with 10 mL saline; an additional Theranostics 2012, 2(6) 
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150 µL saline was added to the column. The product 
was eluted with saline in 250 µL fractions. The frac-
tion  containing  the  greatest  amount  of 
[18F]FBEM-scVEGF  (fraction  4,  range  87.5  –  283.8 
MBq) was used for biological studies.  
For  quality  control  purposes,  a  portion  of  the 
product was re-injected onto an analytical Vydac C-4 
HPLC  column  to  assay  for  radiochemical  purity.  A 
gradient HPLC method was used that began with 5% 
B (0.1% TFA in CH3CN) and 95% A (0.1% TFA in wa-
ter) for 5 min followed by a linear gradient to 65% B at 
35 min. The product eluted at about 23 min as a broad 
tailing  peak.  Specific  activity  was  estimated  from  a 
direct UV measurement of fraction 4.  
Cell Culture and Animal Model 
All animal studies were conducted in accordance 
with  the  principles  and  procedures  outlined  in  the 
Guide for the Care and Use of Laboratory Animals 
and were approved by the Institutional Animal Care 
and Use Committee of Clinical Center, NIH. Porcine 
aortic  endothelial  (PAE)  cells  overexpressing  KDR 
(PAE/KDR) cells were grown in Ham’s F-12 medium 
containing  10%  fetal  bovine  serum  (FBS).  The 
MDA-MB-435 cell line was purchased from the ATCC 
and grown in Leibovitz’s L-15 medium supplemented 
with 10% (v/v) FBS under a 100% air atmosphere at 
37°C. Murine breast cancer cell line 4T1 was grown in 
RPMI-1640 medium supplemented with 10% FBS. The 
human glioma U87MG cell line was purchased from 
ATCC and grown in α-MEM medium supplemented 
with 10% FBS. 4T1 cells and U87MG cells are grown in 
a humidified atmosphere containing 5% CO2 at 37°C. 
The  cells  were  harvested  with  trypsin/EDTA.  The 
MDA-MB-435  tumor  model  was  developed  in  5  to 
6-week old female athymic nude mice by injection of 
5×106 cells in the front shoulder. The 4T1 tumor model 
was developed in 5 to 6-week old female Balb/C mice 
(Harlan Laboratories) by injection of 2×106 cells in the 
right front shoulders. For U87MG tumor model, the 
tumor cells were harvested and resuspended in cold 
PBS, mixed with an equal volume of cold (4°C) liquid 
Matrigel  and  immediately  injected  subcutaneously 
into the right lower flank of 5 to 6-week old female 
athymic  nude  mice  (Harlan  Laboratories).  Tumor 
growth was monitored using caliper measurements of 
perpendicular axes of the tumor. The tumor volume 
was  estimated  by  the  formula:  tumor  volume  = 
a×b2/2,  where  a  and  b  were  the  tumor  length  and 
width, respectively, in millimeters. The mice under-
went  small-animal  PET  studies  when  the  tumor 
volume reached 200–500 mm3 (3–4 weeks after inocu-
lation). 
In Vitro Cellular Binding Activity  
The  cellular  binding  activity  of  FBEM-scVEGF 
was  evaluated  by  competitive  binding  assay  using 
Cy5.5-scVEGF as probe and FBEM-scVEGF as com-
petitor  in  PAE/KDR  cells.  In  brief,  PAE/KDR  cells 
were typsinized, counted, and 104 cells were seeded 
into 8-well Lab-Tek® Chamber slides and allowed to 
grow  overnight.  Then  the  cells  were  fixed  with 
ice-cold acetone for 5 min, washed three times with 
PBS. Modified PBS supplemented with 1 mM CaCl2, 5 
mM MgCl2, 0.5% (w/v) BSA and 0.3 mM NaN3 was 
used for immunofluorescence staining. In each well, 
500  µl  modified  PBS  containing  0.2  µg/ml 
Cy5.5-scVEGF (7 µM) and various concentrations of 
scVEGF or FBEM-scVEGF (ranged from 0-100 µg/ml) 
were  added.  After 30  min  incubation  at  room  tem-
perature,  the  slides  were  washed  three  times  with 
PBS,  mounted  with  medium  containing 
4’,6-diamidino-2-phenylindole  (DAPI)  and  were  ob-
served with an epifluorescence microscope (Olympus, 
X81) equipped with filter sets for both DAPI (excita-
tion, HQ 360 nm; emission, HQ 460 nm) and cyanine 
5.5 (Cy5.5, excitation, HQ 675 nm; emission, HQ 694 
nm).  The  images  were  analyzed  with  Image  J  soft-
ware. RGB images were first split into two grayscale 
channels, representing blue (DAPI staining) and red 
(Cy5.5-scVEGF  binding),  respectively.  Then  signal 
intensity was measured for quantification. Since we 
seeded same number of cells into each well, and the 
cells were allowed to attach to culture vessels for 12 h, 
we  assumed  that  the  cell  numbers  at  staining  time 
were the same. Therefore, we compared fluorescence 
intensity of each well as an indirect method to evalu-
ate cellular binding activity of FBEM-scVEGF.  
In gel autoradiography  
To further confirm the radiolabeling of scVEGF, 
[18F]FBEM-scVEGF and non-labeled scVEGF protein 
were mixed with equal volume of 2× NuPAGE® LDS 
sample  buffer,  and  loaded  onto  Nu-PAGE  4-12% 
Bis-Tris gel. After electrophoresis, the separating gel 
was transferred into a plastic container with lid and 
rinsed briefly in 50 mM Tris·HCl (pH 7.0) to remove 
excess running buffer. Two gels were run in parallel. 
After electrophoresis, one gel was stained with Coo-
massie Blue to visualize the protein bands, the other 
gel  was  placed  onto  an  autoradiography  cassette 
containing a super resolution screen (Packard), read 
by Storage Phosphor System Cyclone Plus using Im-
age Reader BAS-5000 software.,  
Cell Uptake, Internalization, and Efflux Studies 
Cell  uptake,  internalization,  and  efflux  of 
18F-FBEM-scVEGF  protein  were  performed  in Theranostics 2012, 2(6) 
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PAE/KDR cells. For cell uptake, PAE/KDR cells were 
seeded into 24-well plates at a density of 1×105 cells 
per well and incubated with 18.5 kBq /well (7.5-11 ng) 
of [18F]FBEM-scVEGF at 37°C for 15, 30, 60, and 120 
min  with  or  without  an  excess  amount  of  0.1  M 
scVEGF  protein.  The  cells  were  then  washed  three 
times with chilled PBS and lysed with 200 µL 0.1 M 
NaOH.  For  internalization,  the  percentage  of 
[18F]FBEM-scVEGF activity trapped in the cells was 
determined after removing [18F]FBEM-scVEGF activ-
ity bound to the cell surface by washing three times 
with an acid buffer (50 mM glycine and 0.1 M NaCl, 
pH  2.8).  For  efflux  studies,  about  18.5  kBq/well  of 
[18F]FBEM-scVEGF  were  first  incubated  with 
PAE/KDR cells in 24-well plates for 2 h at 37°C. The 
cells were washed three times with chilled PBS and 
allowed to stand with fresh buffer. At various time 
points,  the  medium  was  removed  and  the  cells 
washed three times with chilled PBS. The cells were 
then lysed with 200 µL 0.1 M NaOH. The cell lysate 
was  collected  and  the  remaining  radioactivity  was 
measured in a γ counter (Packard, Meriden, CT). The 
cell uptake, internalization and efflux were expressed 
as the percentage of the added dose (%AD) after de-
cay correction. All experiments were performed three 
times with triplicate wells. 
MicroPET Imaging 
 PET scans and image analysis were performed 
using an Inveon microPET scanner (Siemens Medical 
Solutions). To determine the optimal timing for PET 
imaging,  about  3.7  MBq  [0.05-0.08  nmol  of 
[18F]FBEM-scVEGF]  were  administered  via  tail  vein 
injection  under  isoflurane  anesthesia,  and  10-min 
static PET images were acquired at 0.5, 1.0 and 2.0 h 
post-injection (p.i.; n = 3/group). For VEGFR blocking 
experiment,  5.4  nmol  non-labeled  scVEGF  protein 
was co-injected with 3.7 MBq of [18F]FBEM-scVEGF 
into  4T1  tumor  mice  and  10-min  static  PET  images 
were acquired at 2 h time point (n = 3). PET Images 
were  reconstructed  by  a  3-dimensional  or-
dered-subset expectation  maximum (3D OSEM) fol-
lowed  by  maximum  a  posteriori  (MAP)  algorithm. 
For each scan, regions of interest (ROIs) were drawn 
over the tumor and major organs using vendor soft-
ware (ASI Pro 5.2.4.0) on decay-corrected whole-body 
coronal images. The radioactivity concentrations (ac-
cumulation)  within  the  tumors,  muscle,  liver,  and 
kidneys were obtained from mean pixel values within 
the multiple ROI volume and then converted to MBq 
per milliliter per minute using the calibration factor 
determined for the Inveon PET system. These values 
were  then  divided  by  the  administered  activity  to 
obtain (assuming a tissue density of 1 g/ml) an im-
age-ROI-derived  percent  injected  dose  per  gram 
(%ID/g). 
Biodistribution Studies 
 For  distribution  studies,  about  3.7  MBq  per 
mouse of [18F]FBEM-scVEGF (n = 6) was injected via 
the  tail  vein.  For  VEGFR  blocking  experiment,  5.4 
nmol  non-labeled  scVEGF  protein  was  co-injected 
with 3.7 MBq of [18F]FBEM-scVEGF into tumor mice 
(n = 4). At 2 h p.i., the animals were sacrificed and 
dissected.  Blood,  tumor,  major  organs  and  tissues 
were collected and wet-weighed. The radioactivities 
in the wet whole tissue were counted in a γ-counter 
(Wallac  Wizard  3,  Perkin-Elmer)  along  with  three 
samples of standard activity (1/100 of injected dose). 
Results were calculated as the average of percent in-
jected dose per gram of tissue (%ID/g) ± 1 standard 
deviation of the mean.  
Immunohistochemical Staining 
 Frozen tumor tissue sections (thickness, 5 µm) 
were fixed with cold acetone for 10 min and air dried 
for 30 min at room temperature. After being blocked 
with 2% BSA for 30 min, the sections were incubated 
with  rat  anti-VEGFR2  antibody  (1:100;  Abcam)  and 
rabbit anti-CD31 antibody (1:500; Abcam) for 2 h at r.t. 
After  washing  with  PBS,  the  sections  were  further 
incubated  with  FITC-conjugated  goat  anti-rat  sec-
ondary  antibody  and  Cy3-conjugated  donkey  an-
ti-rabbit  secondary  antibody  (1:500;  Jackson  Immu-
noResearch Laboratories, West Grove, PA) for 1 h at 
r.t. After PBS washing (3×), the slides were mounted 
with  medium  containing  DAPI  and  were  observed 
with an epifluorescence microscope (Olympus, X81) 
equipped  with  filter  sets  for  both  DAPI  (excitation, 
HQ  360  nm;  emission,  HQ  460  nm),  fluorescein 
isothiocyanate (FITC) (excitation, HQ 488 nm; emis-
sion, HQ 520 nm) and Cy3 (excitation, HQ 550 nm; 
emission, HQ 570 nm).  
Data Analysis 
Quantitative data are expressed as mean ± SD. 
Means were analyzed by unpaired, two-tailed t-test 
using  GraphPad  Prism  (version  4.00  for  Windows 
GraphPad Software, San Diego, CA) in order to de-
termine any significant differences (P < 0.05).  
RESULTS 
Chemistry and Radiochemistry 
scVEGF is a 28 kDa fusion protein containing a 
cys-tag  (KESCAKKFQRQHMDS)  at  the  N-terminus. 
After preparation and lyophilization, the sulfhydryl 
functional group remains in a free form and will react Theranostics 2012, 2(6) 
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with thiol specific functional group, e.g. maleimide. A 
small quantity of non-radioactive FBEM-scVEGF was 
prepared  and  the  identity  established  by  ESI-MS. 
ESI-MS  deconvolution  m/z  is  28072  (Calculated 
28086).  The  radioactive  version,  [18F]FBEM-scVEGF 
was prepared in the same manner by using [18F]FBEM 
in the conjugation reaction. The radiochemical yield 
based on starting [18F]FBEM was 20.6 ± 15.1% (n = 5, 
uncorrected) in about 38 min. The radiochemical pu-
rity was assessed by radio-HPLC. The peak for the 
desired  product  was  broad  with  significant  tailing, 
but no other radiochemical peaks were observed. The 
specific activity was estimated from the UV absorb-
ance at 280 nm using the absorbance of unmodified 
scVEGF  as  the  control.  The  value  was  58.8  ±  12.4 
GBq/µmol (n = 3) at the end of synthesis. 
Characterization of [18F]FBEM-scVEGF  
We first evaluated whether FBEM-scVEGF con-
jugate retained its native affinity for VEGFR-2 using 
immunofluorescence  staining  performed  with 
PAE/KDR  cells.  As  shown  in  Figure  1A, 
FBEM-scVEGF  can  effectively  inhibit  Cy5.5-scVEGF 
binding  to  PAE/KDR  cells  in  a  dose-dependent 
manner. The IC50 value of FBEM-scVEGF was 19.98 ± 
5.39  µg/mL,  which  is  slightly  higher  than  that  of 
non-labeled scVEGF (13.99 ± 1.80 µg/mL, P = 0.3516) 
(Figure 1B). The result demonstrated that FBEM con-
jugation  of  scVEGF  did  not  significantly  affect  its 
binding affinity to VEGFRs.  
scVEGF may exist in a mixed form consisting of 
monomers and dimers. In gel autoradiography result 
was  analyzed  by  using  gel  quantification  analysis 
function  in  Image  J.  Ten  microgram  non-labeled 
scVEGF (Figure 1C, lane a) were consisted of 89.6% 
monomer  and  7.8%  dimer,  and  did  not  show  any 
signal in the autoradiography (Figure 1C, lane c). Af-
ter [18F]FBEM labeling, the percentages of monomer 
were 82.1% and 83.6% as assessed by Coomassie Blue 
staining  (Figure  1C,  lane  b)  and  autoradiography 
(Figure  1C,  lane  d),  respectively.  Slightly  increased 
dimer content in the case of autoradiography may be 
a  result  of  air  oxidation  of  cysteine  during  radio-
labeling procedure.  
The cell uptake and efflux of [18F]FBEM-scVEGF 
were evaluated in PAE/KDR cells. As shown in Fig-
ure  1D,  uptake  of  18F-FBEM-scVEGF  by  PAE/KDR 
cells increased with time, which peaked after 60 min 
incubation.  The  total  cell  uptake  values  of 
18F-FBEM-scVEGF were 8.62 ± 0.41, 12.85 ± 0.13, 16.89 
± 0.55, and 13.51 ± 0.51 percent of added dose (%AD) 
after 15, 30, 60, and 120 min incubation, respectively. 
[18F]FBEM-scVEGF also showed a relatively high level 
of internalization, with 8.46 ± 0.63, 12.73 ± 0.28, 15.38 ± 
0.89, and 12.34 ± 0.38 %AD radioactivity internalized 
after 15, 30, 60, and 120 min incubation, respectively 
(Figure  1D,  internalization).  Complete  inhibition  of 
cell  uptake  was  observed  with  the  presence  of  100 
µg/ml scVEGF protein, confirming the specificity of 
VEGFR2  mediated  cell  uptake  (Figure  1D,  Block). 
When the labeled cells were incubated in serum-free 
medium  devoid  of  radioactivity,  [18F]FBEM-scVEGF 
showed efflux from the cells with time (Figure 1E). 
After 1 h, approximately 50% of the radioactivity was 
dissociated from the cells.  
Serial PET imaging Studies With 
[18F]FBEM-scVEGF  
To  determine  the  in  vivo  kinetics, 
[18F]FBEM-scVEGF  was  injected  intravenously  into 
MDA-MB-435  tumor  bearing  mice  and  microPET 
scans  were  carried  out  at  various  time  points  p.i. 
Representative coronal slices that contained the tumor 
were  shown  in  Figure  2.  The  tumor  uptake  of 
[18F]FBEM-scVEGF was 0.64 ± 0.14, 1.41 ± 0.53, and 
1.38 ± 0.38 %ID/g at 0.5, 1.0, and 2.0 h p.i., respec-
tively. Although the tumor uptake was comparable at 
1.0  h  and  2.0  h  p.i.,  the  tumor-to-background  ratio 
increased  over  time.  Tumor-to-muscle  ratio  was  in-
creased by 63.8% from 1.06 ± 0.14 at 0.5 h p.i. to 1.74 ± 
0.29 at 2.0 h; tumor-to-kidney ratio was increased by 
1.96-fold from 0.056 ± 0.124 at 0.5 h p.i. to 0.166 ± 0.023 
at 2 h p.i. Tumor-to-organ ratios are essential as they 
determine imaging contrast and sensitivity; therefore, 
we choose 2 h time point for other experiments.  
[18F]FBEM-scVEGF PET Imaging in U87MG 
Tumor Model 
The  data  concerning  in  vivo  distribution  of 
[18F]FBEM-scVEGF in U87MG tumor-bearing athymic 
nude mice were presented in Figure 3. Kidney uptake 
of  [18F]FBEM-scVEGF  in  these  U87MG  tumor  mice 
was relatively high with 27.2 ± 4.9 %ID/g at 2 h p.i. (n 
= 5). The tumor uptake of [18F]FBEM-scVEGF at 2 h 
time point was 0.340 ± 0.03 %ID/g, at which the mus-
cle  uptake  of  [18F]FBEM-scVEGF  was  0.22  ±  0.04 
%ID/g.  Tumor-to-muscle  ratio  was  1.78  ±  0.25. 
Therefore,  [18F]FBEM-scVEGF  PET  images  provided 
reasonably good signal-to-noise ratio. Pre-saturation 
of  the  receptor  by  excess  amount  of  non-labeled 
scVEGF  protein  (150  µg/mouse)  resulted  in  36.05% 
decrease (n = 3, P = 0.0003) of radioactivity accumula-
tion as compared with non-blocking group (Fig. 4C), 
which  demonstrated  that  tumor  uptake  of 
[18F]FBEM-scVEGF was VEGFR specific.  Theranostics 2012, 2(6) 
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Figure 1. Characterization of FBEM-scVEGF conjugates and [18F]FBEM-scVEGF. (A) Inhibition of Cy5.5-scVEGF (Red) binding to VEGFR2 
overexpressed on PAE/KDR cells by different concentrations of non-labeled scVEGF and FBEM-conjugated scVEGF. (B) The IC50 values 
were 19.98±5.39 µg/ml and 13.99±1.80 µg/ml for FBEM-scVEGF and scVEGF, respectively as determined by relative fluorescence units 
derived from images in (A) by Image J software. (C) In gel autoradiography showed that 18F-FBEM-scVEGF existed as a mixture of 
monomer and dimer. (a-d) showed scVEGF protein and [18F]FBEM-scVEGF stained with Coomassie blue (a and b, respectively), or 
autoradiography (c and d, respectively). (D) Cell uptake, internalization and efflux (E) assay of [18F]FBEM-scVEGF on PAE/KDR cells. Data 
were from 2 experiments with triplicate samples and are expressed as mean ± SD. AD, total added dose. Theranostics 2012, 2(6) 
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Figure 2. PET study in MDA-MB-435 tumor-bearing mice. Decay-corrected whole-body coronal microPET images of athymic female 
nude mice bearing MDA-MB-435 tumor at 0.5 h (A), 1 h (B) and 2 h (C) after injection of [18F]FBEM-scVEGF (3.7MBq).  
 
Figure 3. PET study in U87MG tumor-bearing mice. Decay-corrected whole-body coronal microPET images of athymic nude mice 
bearing U87MG tumors at 2 h p.i. of [18F]FBEM-scVEGF (3.7MBq), unblocked (A) and blocked (B). (C) Tumor-to-kidney and tu-
mor-to-muscle ratios at 2 h p.i. of [18F]FBEM-scVEGF. (D) Uptake values at 2 h p.i. in the U87MG tumor in the presence or absence of 
scVEGF protein.  
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Figure 4. PET study in 4T1 tumor-bearing mice. Decay-corrected whole-body coronal microPET images of Balb/C mice bearing 4T1 
tumors at 2 h p.i. of [18F]-FBEM-scVEGF (3.7MBq), unblocked (A) and blocked (B). (C) Uptake values at 2 h p.i. in the 4T1 tumor in the 
presence or absence of scVEGF protein. (D) Biodistribution of [18F]FBEM-scVEGF in Balb/C mice bearing subcutaneous 4T1 tumors after 
microPET imaging at 2 h time point (n = 6). 
 
 
[18F]FBEM-scVEGF PET Imaging and Biodis-
tribution in 4T1 Tumor Model 
Furthermore, we performed microPET imaging 
of  [18F]FBEM-scVEGF  in  4T1  tumor-bearing  Balb/C 
mice. Representative coronal images were shown in 
Figure  4A  and  4B.  The  tumor  uptake  of 
[18F]FBEM-scVEGF was 0.82 ± 0.04 %ID/g at 2 h p.i. 
(Fig.  4A).  Pre-saturation  of  the  receptors  by  excess 
amount  of  non-labeled  scVEGF  protein  (150 
µg/mouse) resulted in 48.02% decrease (P = 0.004) of 
radioactivity  accumulation  as  compared  with 
non-blocking group (Fig. 4C).  
The accuracy of PET imaging quantification was 
further  confirmed  by  biodistribution  study  of 
[18F]FBEM-scVEGF  in  4T1  tumor  mice  immediately 
after PET imaging. Besides the kidneys, the lung and 
intestine also had significant tracer uptake. The lung 
has  been  reported  to  express  both  VEGFR-1  and 
VEGFR-2 [14, 15], and significant uptake in the lung 
was also observed in previous reports of VEGF-based 
tracers [10, 16]. The tumor/muscle ratio was 2.19 ± 
0.54 at 2 h time point. The quantification results ob-
tained  from  biodistribution  studies  and  PET  scans 
were similar for the 4T1 tumor and most organs, con-
firming that quantitative ROI analysis of noninvasive 
microPET  scans  truly  reflects  the  biodistribution  of 
[18F]FBEM-scVEGF in vivo.  
To  confirm  the  VEGFR  specificity  of 
18F-FBEM-scVEGF in vivo, blocking experiments were 
carried out where 150 µg of scVEGF was co-injected 
with [18F]FBEM-scVEGF into 4T1 tumor-bearing mice. 
The tumor uptake was significantly reduced to 0.68 ± 
0.15  %ID/g,  confirming  VEGFR  specificity  of  the 
tracer (Fig. 4D).  
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Figure 5. Immunofluorescence staining of VEGFR2 and CD31 for MDA-MB-435, U87MG, and 4T1 tumors. The tissue sections were 
stained with anti-VEGFR2 antibody (green) to identify VEGFR2 expression, anti-CD31 antibody (red) to identify vasculature, and DAPI 
(blue) to identify nuclei. 
 
Immunofluorescence Staining  
To  evaluate  VEGFR  expression  in  each  tumor 
tissue, immunofluorescence staining was carried out, 
and  representative  images  of  CD31  and  VEGFR-2 
staining  of  MDA-MB-435,  U87MG  and  4T1  tumor 
tissue  slices  were  shown  in  Figure  5.  The  results 
showed  strong  VEGFR-2  staining  in  both 
MDA-MB-435 and 4T1 tumors, and relatively weaker 
staining in U87MG tumors, which was consistent with 
the  PET  imaging  results  that  MDA-MB-435  tumors 
and  4T1  tumors  have  higher  tumor  uptake  than 
U87MG tumors.  
DISCUSSION  
An accurate assessment of VEGFR expression is 
crucial for the selection of patients that may benefit 
from  VEGFR-targeted  therapies.  Currently,  ex  vivo 
techniques, such as immunohistochemistry and fluo-
rescence  in  situ  hybridization,  are  used  to  estimate 
VEGFR  expression  before  recommending 
VEGFR-targeted  molecular  therapies.  Downstream 
effects of VEGFR-directed therapy are imaged in the 
clinic  by  computed  tomography  (CT)  and  dynamic 
contrast-enhanced  magnetic  resonance  imaging 
(DCE-MRI). However, molecular imaging of the drug 
target itself, such as VEGFRs, provides critical infor-
mation on the target prevalence, opening opportuni-
ties for treatment management and optimization. The 
high resolution, sensitivity, and quantitative nature of 
PET  imaging  offer  an  ideal  method  for  assessing 
VEGFR  expression  status.  Radiotracers  suitable  for 
non-invasive imaging of  VEGFRs  in vivo have been Theranostics 2012, 2(6) 
 
http://www.thno.org 
616 
previously  reported.  Different  fragments  of  VEGF 
labeled with 64Cu have been used for VEGFR imaging, 
such  as  64Cu-DOTA-VEGF121/rGel  [4],  64Cu-DOTA- 
VEGF121,  64Cu-DOTA-VEGFDEE, etc. [17]; small mole-
cules inhibitors acting on the intracellular TK domain 
of the VEGF receptors has been labeled with short-
er-lived radioisotopes to image VEGF receptors more 
frequently  throughout  a  therapeutic  protocol  [18]. 
scVEGF  has  been  labeled  in  a  site-specific  manner 
with a variety of agents for VEGFR imaging. For ex-
ample,  68Ga-N,N’-bis[2-hydroxy-5-(carboxyethyl) 
benzyl]ethylenediamine-N,N’-diacetic  ac-
id-PEG-scVEGF  (68Ga-HBED-CC-PEG-scVEGF)  [19], 
68Ga-1,4,7-triazacyclononane-1,4,7-triacetic  ac-
id-PEG-scVEGF  (68Ga-NOTA-PEG-scVEGF)  [19]; 
64Cu-DOTA-scVEGF  and  99mTc-hydrazinonicotinic 
acid  (HYNIC)-scVEGF  (99mTc-HYNIC-scVEGF)  [10], 
etc. 
This  article  has  described  the  synthesis  of 
18F-labeled scVEGF at pre-designed C4-cysteine resi-
due  to  allow  radiolabeling  with  the  thiol-specific 
prosthetic group, FBEM. Our data showed that FBEM 
conjugation of scVEGF doesn’t affect binding affinity 
of scVEGF protein. [18F]FBEM-scVEGF can be specif-
ically  internalized  into  VEGFR2  overexpressing 
PAE/KDR  cells.  In vivo  PET  imaging  demonstrated 
VEGFR-mediated  [18F]FBEM-scVEGF  uptake  in  sev-
eral xenograft models.  
Modification  of  a  targeting  ligand  for  imaging 
applications should always be performed with utmost 
caution, since in many cases non-specific conjugation 
of  chelators  (for  radiometal  labeling)  or  other  pros-
thetic groups (e.g. for 11C/18F-labeling) may affect the 
target  binding  affinity/specificity  of  the  ligand. 
scVEGF is an engineered 28 kDa single-chain VEGF, 
consisting of two 3-112 fragments of human VEGF121 
cloned  head-to-tail  and  fused  to  an  N-terminal 
Cys-tag with C4-thiol group. The available free thiol 
of  the  C-4  thiol  group  reacted  specifically  with  the 
maleimide  of  FBEM  to  provide  the  site-specifically 
labeled  [18F]FBEM-scVEGF.  Site-specific  conjugation 
of  the  prosthetic  group  FBEM  did  not  affect  its 
VEGFR-2 binding affinity as indicated by competitive 
binding assay. The variability in both the yield and 
the specific activity of the obtained product was due 
to variation in the stoichiometry of the reaction and 
the input amount of scVEGF protein. In one case, we 
attempted  to  increase  the  yield  of  product  by  dou-
bling the amount of substrate protein used. This re-
sulted  in  a  dramatic  increase  in  the  radiochemical 
yield but no real change in the specific activity of the 
resulting  product.  The  specific  activity  of  the  pros-
thetic [18F]FBEM was not measured, but historically 
was observed to be in the range between 180 and 350 
GBq/µmol at the end of bombardment [20]. This spe-
cific activity is subject to the cyclotron irradiation pa-
rameters and the time of the synthesis. Thus at time of 
synthesis for the protein, the lowest radioactivity that 
we used (577.2 MBq) led to the lowest specific activity 
of 90 GBq/µmol (correction of 180 GBq/µmol by one 
half-life) would mean that we added 6.4 nmol FBEM. 
The amount of protein used for the synthesis was 3.6 
nmol or in one case 7.2 nmol. Therefore the protein 
was in molar deficiency in most cases. This explains 
the relatively low yield and the large yield increase 
when the amount of protein was doubled.   
[18F]FBEM-scVEGF  showed  favorable  in  vivo 
distribution.  First,  kidney  accumulation  of 
[18F]FBEM-scVEGF  is  lower  than  other  radiometal 
labeled scVEGF probes. The average kidney uptakes 
of  68Ga-labeled scVEGF at 2 h p.i. were 179.0 ± 20.0 
and  118.5  ±  3.6  %ID/g  for  scVEGF-PEG-HBEM-CC 
and  scVEGF-PEG-NOTA,  respectively  [19]. 
[18F]FBEM-scVEGF proved to be efficient in decreas-
ing nonspecific renal uptake, which was only 9.17 ± 
0.25  %ID/g  in  4T1  tumor-bearing  Balb/C  mice.  In 
addition, the liver uptake of [18F]FBEM-scVEGF was 
1.31  ±  0.18  %ID/g,  lower  than  that  reported  for 
68Ga-labeled  scVEGF  (3.62  ±  1.11  and  5.43  ±  0.76 
%ID/g  for  scVEGF-PEG-HBEM-CC  and 
scVEGF-PEG-NOTA),  99mTc-labeled scVEGF (around 
6 %ID/g) and 64Cu-labeled scVEGF (7-8%ID/g).  
The  absolute  tumor  uptake  of  [18F]FBEM- 
scVEGF is low compared to other reports using ra-
diometal  labeled  VEGFR  targeting  PET  tracers.  For 
example, tumor uptake  of  64Cu-DOTA-VEGF121  was 
4.6 ± 0.5 %ID/g at 4 h p.i. in 4T1 tumor models [21], 
whereas that of [18F]FBEM-scVEGF at 2 h was 0.82 ± 
0.04 %ID/g. However, due to different properties of 
each radionuclide and radiochemistry applied during 
labeling procedure, direct literature data comparison 
is  insufficient  to  draw  a  conclusion  concerning  the 
advantages and disadvantages of particular formats 
of  imaging  agents.  Furthermore,  from  coronal  PET 
images shown in Figure 4A, we can see a hot spot in 
the upper abdomen which suggested gallbladder ac-
cumulation of radioactivity, which may be explained 
by the fact that [18F]FBEM-scVEGF is not very stable in 
vivo  and  the  hydrophobic  group  in  the  tracer  was 
chopped off and accumulated in the gallbladder. We 
will  further  modify  radiochemistry  strategy  to  in-
crease  the  stability  of  18F-labeled  scVEGF,  increase 
tumor uptake and decrease the tracer accumulation in 
other organs. 
CONCLUSION  
The new tracer [18F]FBEM-scVEGF was synthe-
sized  with  reasonably  high  specific  activity  via Theranostics 2012, 2(6) 
 
http://www.thno.org 
617 
[18F]FBEM  and  the  tracer  exhibited  high  receptor 
binding affinity, tumor targeting efficacy, and favor-
able in vivo distribution for imaging contrast, although 
at a cost of lower tumor  uptake and weaker signal 
from tumors. This tracer is expected to have potential 
for  noninvasive  PET  imaging  of  VEGFR  expression 
for  tumor  diagnosis  and  prediction  of  cancer  treat-
ment response.  
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